# Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

> clinical trial · VERIFIED · 2026-07-23

Status: RECRUITING · Sponsor: OSE Immunotherapeutics · Condition: Patients With Non-Small Cell Lung Cancer

- Company: OSE Immunotherapeutics
- Sector: Patients With Non-Small Cell Lung Cancer
- Primary source: https://clinicaltrials.gov/study/NCT06472245

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.